As consumer awareness of preventive wellness continues to rise, growing attention toward Helicobacter pylori screening has also accelerated demand in the digestive wellness market. Pylopass®, a patented European postbiotic ingredient, has recently become a key topic within the global functional food industry.

Derived from the patented strain Lactobacillus reuteri DSM17648, Pylopass® is developed using a unique postbiotic technology that provides excellent stability and versatile application potential. Unlike conventional probiotic concepts, Pylopass® is recognized for its precise targeting capability, allowing it to specifically recognize targeted bacterial surface structures.

The Novonesis research team screened more than 700 lactic acid bacteria strains before identifying this highly specific patented strain. Through its unique co-aggregation technology, Pylopass® can bind with targeted bacterial structures and form aggregates, attracting increasing attention in international markets.

Pylopass® has obtained multiple international patents and certifications, including GRAS, Halal, and EU QPS recognition, and is supported by published scientific literature. The ingredient has already been successfully commercialized across Europe, Asia, and the Americas.

As the global wellness industry continues evolving toward convenience, daily wellness integration, and food-style supplementation, consumers are placing greater emphasis on scientific credibility, ingredient transparency, and user experience. With its room-temperature stability and flexible formulation advantages, Pylopass® is becoming an important ingredient choice for next-generation functional food development.